Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Waleed Ghanima

Showing results (121-130 of 205) with videos related to

Pageof 21
Sort By:
British Journal of Haematology|August 5, 2024
Platelet response to romiplostim amongst patients with newly diagnosed, persistent, and chronic immune thrombocytopenia in routine clinical practice in Denmark, Sweden, and NorwayChristian Fynbo Christiansen, Nickolaj Risbo, Waleed Ghanima, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|March 27, 2024
Real-world Data on Treatment Patterns and Bleeding in Cancer-associated Thrombosis: Data from the TROLL RegistryZygimantas Zaboras, Camilla Tøvik Jørgensen, Andreas Stensvold, et al.
British Journal of Haematology|September 10, 2011
Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agentsWaleed Ghanima, Peter Junker, Hans Carl Hasselbalch, et al.
Platelets|January 3, 2018
Immune thrombocytopenia is associated with persistently deranged fibrosis-related seromarker profiles but low bone marrow fibrosis grades: A 2-year observational study on thrombopoietin receptor agonist treatmentWaleed Ghanima, Leonardo Boiocchi, Christina S Lee, et al.
Lancet (London, England)|February 10, 2015
Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trialWaleed Ghanima, Abderrahim Khelif, Anders Waage, et al.
Blood|April 9, 2004
Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patientsSigbjørn Berentsen, Elling Ulvestad, Bjørn Tore Gjertsen, et al.
Journal of Thrombosis and Haemostasis : JTH|September 26, 2021
Statins for venous event reduction in patients with venous thromboembolism: A multicenter randomized controlled pilot trial assessing feasibilityAurélien Delluc, Waleed Ghanima, Michael J Kovacs, et al.
Thrombosis Research|June 25, 2023
Demographic, clinical, and echocardiographic factors associated with residual perfusion defects beyond six months after pulmonary embolismØyvind Jervan, Adam Dhayyat, Jostein Gleditsch, et al.
Thrombosis Research|March 28, 2022
Prevention of post-thrombotic syndrome with rosuvastatin: A multicenter randomized controlled pilot trial (SAVER)Aurélien Delluc, Waleed Ghanima, Michael J Kovacs, et al.
Thrombosis Update|April 15, 2024
Thromboembolic complications during and after hospitalization for COVID-19: Incidence, risk factors and thromboprophylaxisBirgitte Tholin, Hilde Fiskvik, Anders Tveita, et al.
Pageof 21

Showing results (121-130 of 205) with videos related to

Sort By:
Pageof 21
British Journal of Haematology|August 5, 2024
Platelet response to romiplostim amongst patients with newly diagnosed, persistent, and chronic immune thrombocytopenia in routine clinical practice in Denmark, Sweden, and NorwayChristian Fynbo Christiansen, Nickolaj Risbo, Waleed Ghanima, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|March 27, 2024
Real-world Data on Treatment Patterns and Bleeding in Cancer-associated Thrombosis: Data from the TROLL RegistryZygimantas Zaboras, Camilla Tøvik Jørgensen, Andreas Stensvold, et al.
British Journal of Haematology|September 10, 2011
Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agentsWaleed Ghanima, Peter Junker, Hans Carl Hasselbalch, et al.
Platelets|January 3, 2018
Immune thrombocytopenia is associated with persistently deranged fibrosis-related seromarker profiles but low bone marrow fibrosis grades: A 2-year observational study on thrombopoietin receptor agonist treatmentWaleed Ghanima, Leonardo Boiocchi, Christina S Lee, et al.
Lancet (London, England)|February 10, 2015
Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trialWaleed Ghanima, Abderrahim Khelif, Anders Waage, et al.
Blood|April 9, 2004
Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patientsSigbjørn Berentsen, Elling Ulvestad, Bjørn Tore Gjertsen, et al.
Journal of Thrombosis and Haemostasis : JTH|September 26, 2021
Statins for venous event reduction in patients with venous thromboembolism: A multicenter randomized controlled pilot trial assessing feasibilityAurélien Delluc, Waleed Ghanima, Michael J Kovacs, et al.
Thrombosis Research|June 25, 2023
Demographic, clinical, and echocardiographic factors associated with residual perfusion defects beyond six months after pulmonary embolismØyvind Jervan, Adam Dhayyat, Jostein Gleditsch, et al.
Thrombosis Research|March 28, 2022
Prevention of post-thrombotic syndrome with rosuvastatin: A multicenter randomized controlled pilot trial (SAVER)Aurélien Delluc, Waleed Ghanima, Michael J Kovacs, et al.
Thrombosis Update|April 15, 2024
Thromboembolic complications during and after hospitalization for COVID-19: Incidence, risk factors and thromboprophylaxisBirgitte Tholin, Hilde Fiskvik, Anders Tveita, et al.
Pageof 21